Tumour Angiogenesis

Summary

Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous "preview", "highlight" or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.

144 Publications

Strategic lines

Selected Publications

Non-invasive and quantitative in vivo monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies.

Mireles M, Morales-Dalmau J, Johansson JD, Vidal-Rosas EE, Vilches C, Martínez-Lozano M, Sanz V, de Miguel I, Casanovas O, Quidant R, Durduran T

NANOSCALE (ISSN: 2040-3364) 2019

Quantification of gold nanoparticle accumulation in tissue by two-photon luminescence microscopy

Morales-Dalmau J., Vilches C., Sanz V., De Miguel I., Rodríguez-Fajardo V., Berto P., Martínez-Lozano M., Casanovas O., Durduran T., Quidant R.

NANOSCALE (ISSN: 2040-3364) 2019

Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents.

Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín L, Soler A, Martínez-Lozano M, Pons R, Llena J, Palomero L, Graupera M, Casanovas O

CANCER RESEARCH (ISSN: 0008-5472) 2019

Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?

Castet F, Garcia-Mulero S, Sanz-Pamplona R, Cuellar A, Casanovas O, Caminal JM, Piulats JM

CANCERS (ISSN: 2072-6694) 2019

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

Capdevila, J; Teule, A; Barriuso, J; Castellano, D; Lopez, C; Manzano, JL; Alonso, V; Garcia-Carbonero, R; Dotor, E; Matos, I; Custodio, A; Casanovas, O; Salazar, R

ONCOLOGIST (ISSN: 1083-7159) 2019

Selected Projects

Mecanismos y Bloqueo de la Resistencia Intrínseca a los Anti-Angiogénicos en Cáncer Renal

Casanovas Casanovas, Oriol (Principal investigator (PI))

Funder:

MINISTERIO DE EDUCACION Y CIENCIA

30/12/2016 - 29/12/2019

Desarrollo de un nuevo biomarcador y su kit para predecir la Resistencia a Antiangiogénicos en Cancer - AngioBIOMARK

Casanovas Casanovas, Oriol (Principal investigator (PI))

Funder:

FIS-Instituto de Salud Carlos III

1/1/2018 - 31/12/2019

Angiotheragnostics

Casanovas Casanovas, Oriol (Principal investigator (PI))

Funder:

Fundació "La Caixa"

1/12/2019 - 31/5/2021

Interacció Tumor Estroma en Resistència Terapèutica (ITERT)

Casanovas Casanovas, Oriol (Principal investigator (PI))

Funder:

AGAUR-GENERAL.CATALUNYA

1/1/2018 - 31/12/2020

More Information

2015 Proof of Concept (PoC) grant from the European Research Council – Oriol Casanovas.

Mapping the pathogenesis of vascular malformations
IP: Graupera Garcia-Mila, Mariona (Project Leader)
Partners: Centro Nacional de Investigaciones Cardiovasculares-CNIC (Dr. R. Benedito), Hospital Santa Creu Sant Pau (Dra. E. Baselga) i Sant Joan de Déu (Dr. J. Mora)
Call: Health Research 2018 Call for proposals, expediente: HR18-00120
Funding Entity: Fundació “la Caixa”